

# Daniel J Powell Jr

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5251583/publications.pdf>

Version: 2024-02-01

63  
papers

5,482  
citations

109321

35  
h-index

118850

62  
g-index

66  
all docs

66  
docs citations

66  
times ranked

7520  
citing authors

#	ARTICLE	IF	CITATIONS
1	Systematic analysis of CD39, CD103, CD137, and PD-1 as biomarkers for naturally occurring tumor antigen-specific TILs. <i>European Journal of Immunology</i> , 2022, 52, 96-108.	2.9	26
2	Epigenetic state determines inflammatory sensing in neuroblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	21
3	PTEN Loss and BRCA1 Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100159.	3.0	4
4	Humanized Patient-Derived Xenograft Models of Ovarian Cancer. <i>Methods in Molecular Biology</i> , 2022, 2424, 255-274.	0.9	3
5	CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy. <i>Nature Communications</i> , 2021, 12, 877.	12.8	143
6	Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer. <i>Npj Vaccines</i> , 2021, 6, 36.	6.0	27
7	Folate Receptor Beta as a Direct and Indirect Target for Antibody-Based Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5572.	4.1	11
8	Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. <i>Nature Communications</i> , 2021, 12, 4365.	12.8	53
9	Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies. , 2021, 9, e002444.		12
10	Engineering-enhanced CAR T cells for improved cancer therapy. <i>Nature Cancer</i> , 2021, 2, 780-793.	13.2	60
11	NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 146.	6.2	67
12	Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. <i>Cancer Cell</i> , 2021, 39, 1623-1642.e20.	16.8	64
13	Induction of IL19 expression through JNK and cGAS-STING modulates DNA damage-induced cytokine production. <i>Science Signaling</i> , 2021, 14, eaba2611.	3.6	1
14	CAR T Cells Targeting MISIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies. <i>Molecular Therapy</i> , 2020, 28, 548-560.	8.2	23
15	An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 156, 222-232.	1.4	37
16	PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response. <i>Molecules</i> , 2020, 25, 6029.	3.8	20
17	A Novel Approach for the Treatment of T Cell Malignancies: Targeting T Cell Receptor V $\beta$ Families. <i>Vaccines</i> , 2020, 8, 631.	4.4	2
18	CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape. <i>Frontiers in Immunology</i> , 2020, 11, 1109.	4.8	165

#	ARTICLE	IF	CITATIONS
19	<i>BRCA</i> Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 665-679.	3.0	29
20	Quantitative Control of Gene-Engineered T-Cell Activity through the Covalent Attachment of Targeting Ligands to a Universal Immune Receptor. <i>Journal of the American Chemical Society</i> , 2020, 142, 6554-6568.	13.7	36
21	Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1814-1823.	1.6	202
22	Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. <i>Cancer Cell</i> , 2019, 35, 885-900.e10.	16.8	475
23	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. <i>Cancer</i> , 2019, 125, 1963-1972.	4.1	39
24	The Emergence of Universal Immune Receptor T Cell Therapy for Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 176.	2.8	64
25	NKG2D CAR-Expressing Lymphocytes Target Acute Myeloid Leukemia Cells. <i>Blood</i> , 2019, 134, 2667-2667.	1.4	1
26	Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	326
27	Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells. <i>Journal of Hematology and Oncology</i> , 2018, 11, 92.	17.0	69
28	NKG2D-CAR Transduced Primary Natural Killer Cells Efficiently Target Multiple Myeloma Cells. <i>Blood</i> , 2018, 132, 590-590.	1.4	20
29	T-cell target antigens across major gynecologic cancers. <i>Gynecologic Oncology</i> , 2017, 145, 426-435.	1.4	24
30	The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy. <i>Vaccines</i> , 2016, 4, 43.	4.4	35
31	Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo. <i>Oncotarget</i> , 2016, 7, 82354-82368.	1.8	31
32	Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 143, 120-127.	1.4	90
33	Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level. <i>Journal of Hematology and Oncology</i> , 2016, 9, 56.	17.0	97
34	Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma. <i>Molecular Therapy</i> , 2016, 24, 1602-1614.	8.2	101
35	Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy. <i>Molecular Therapy</i> , 2016, 24, 1987-1999.	8.2	38
36	A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity. <i>Oncotarget</i> , 2015, 6, 21533-21546.	1.8	76

#	ARTICLE	IF	CITATIONS
37	Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 1130-1137.	3.4	33
38	Tumor infiltrating lymphocytes in ovarian cancer. <i>Cancer Biology and Therapy</i> , 2015, 16, 807-820.	3.4	257
39	Targeting of folate receptor $\beta^2$ on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. <i>Blood</i> , 2015, 125, 3466-3476.	1.4	148
40	CD4+ T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8+ T-cell Targeting of HER2-expressing Cancers. <i>Cancer Immunology Research</i> , 2015, 3, 455-463.	3.4	27
41	Strain-dependent Lethal Toxicity in NKG2D Ligand-targeted CAR T-cell Therapy. <i>Molecular Therapy</i> , 2015, 23, 1559-1561.	8.2	13
42	Advances and prospects in adoptive cell transfer therapy for ovarian cancer. <i>Immunotherapy</i> , 2015, 7, 473-476.	2.0	5
43	T Cells Bearing a Chimeric Antigen Receptor against Prostate-Specific Membrane Antigen Mediate Vascular Disruption and Result in Tumor Regression. <i>Cancer Immunology Research</i> , 2015, 3, 68-84.	3.4	84
44	Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor. <i>Oncotarget</i> , 2015, 6, 28911-28928.	1.8	45
45	Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells. <i>Journal of Translational Medicine</i> , 2014, 12, 347.	4.4	32
46	B7-H4 as a potential target for immunotherapy for gynecologic cancers: A closer look. <i>Gynecologic Oncology</i> , 2014, 134, 181-189.	1.4	45
47	CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor. <i>Clinical Cancer Research</i> , 2014, 20, 44-55.	7.0	241
48	A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside. <i>Clinical Cancer Research</i> , 2013, 19, 4801-4815.	7.0	178
49	IL-21 in cancer immunotherapy. <i>Oncolmmunology</i> , 2013, 2, e24522.	4.6	32
50	Finding a needle in a haystack. <i>Oncolmmunology</i> , 2013, 2, e27184.	4.6	9
51	Chimeric NKG2D CAR-Expressing T Cell-Mediated Attack of Human Ovarian Cancer Is Enhanced by Histone Deacetylase Inhibition. <i>Human Gene Therapy</i> , 2013, 24, 295-305.	2.7	87
52	A Universal Strategy for Adoptive Immunotherapy of Cancer through Use of a Novel T-cell Antigen Receptor. <i>Cancer Research</i> , 2012, 72, 1844-1852.	0.9	264
53	Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor. <i>Molecular Therapy</i> , 2012, 20, 633-643.	8.2	161
54	Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy. <i>Oncolmmunology</i> , 2012, 1, 547-549.	4.6	49

#	ARTICLE	IF	CITATIONS
55	CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. <i>Blood</i> , 2012, 119, 696-706.	1.4	296
56	A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. <i>Journal of Translational Medicine</i> , 2012, 10, 157.	4.4	95
57	Primary Human Ovarian Epithelial Cancer Cells Broadly Express HER2 at Immunologically-Detectable Levels. <i>PLoS ONE</i> , 2012, 7, e49829.	2.5	60
58	Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes. <i>Journal of Translational Medicine</i> , 2011, 9, 131.	4.4	52
59	<i>In Vivo</i> Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB). <i>Cancer Research</i> , 2011, 71, 4617-4627.	0.9	256
60	Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor. <i>Clinical Cancer Research</i> , 2011, 17, 4719-4730.	7.0	441
61	Mannose Receptor (MR) Engagement by Mesothelin GPI Anchor Polarizes Tumor-Associated Macrophages and Is Blocked by Anti-MR Human Recombinant Antibody. <i>PLoS ONE</i> , 2011, 6, e28386.	2.5	34
62	Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program. <i>Cytotherapy</i> , 2009, 11, 923-935.	0.7	43
63	Of mice and men: pre-clinical models to identify therapy responsive patient subgroups. <i>Gynecology and Pelvic Medicine</i> , 0, 3, 13-13.	0.1	1